Furthermore, by acting as AR antagonists, the studied cannabinoids may also be attractive for other pathological conditions where AR antagonists could be clinically applied, such as prostate cancer and benign prostatic hyperplasia [115,116]. The gene discussed is AR; the disease is benign prostatic hyperplasia.